Jeffrey M. Leiden - Apr 13, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Executive Chairman, Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 13, 2022
Transactions value $
-$4,563,653
Form type
4
Date filed
4/14/2022, 04:35 PM
Previous filing
Feb 28, 2022
Next filing
Jul 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$4.56M -15.8K -17.55% $289.04 74.2K Apr 13, 2022 Direct F1, F2, F3
holding VRTX Common Stock 440 Apr 13, 2022 401(k)
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
F2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $289.04 (range $289.00 to $289.58).